This demonstrates that insulin resistance is likely implicated in the early stages of MASLD/MASH, and that the loss of CEACAM1 in the two most prominent cell populations in the liver constitutes a unifying mechanism underlying hepatic fibrosis (and inflammation) in the advanced stages of the disease. The gene discussed is CEACAM1; the disease is metabolic dysfunction-associated steatohepatitis.